Sanara MedTech Inc. (SMTI)
| Market Cap | 172.21M -32.9% |
| Revenue (ttm) | 103.12M +19.0% |
| Net Income | -37.56M |
| EPS | -4.36 |
| Shares Out | 9.16M |
| PE Ratio | n/a |
| Forward PE | 163.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,746 |
| Open | 18.92 |
| Previous Close | 18.93 |
| Day's Range | 18.30 - 18.96 |
| 52-Week Range | 16.05 - 35.95 |
| Beta | 1.10 |
| Analysts | Strong Buy |
| Price Target | 34.00 (+80.95%) |
| Earnings Date | May 12, 2026 |
About SMTI
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-... [Read more]
Financial Performance
In 2025, Sanara MedTech's revenue was $103.12 million, an increase of 18.97% compared to the previous year's $86.67 million. Losses were -$37.56 million, 288.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SMTI stock is "Strong Buy." The 12-month stock price target is $34.0, which is an increase of 80.95% from the latest price.
News
Sanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026
FORT WORTH, TX, April 14, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company”, “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commerciali...
Sanara MedTech, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sanara MedTech, Inc. , (“ Sanara " or the "Company") ( NASDAQ : SMTI) investors that the firm has initiated an investigati...
Sanara MedTech Earnings Call Transcript: Q4 2025
Record 2025 revenue of $103.1M (up 19% YoY) and 93% gross margin reflect strong execution and focus on surgical markets. 2026 guidance projects 13–17% revenue growth, with new Vizient contract and clinical evidence supporting further expansion.
Sanara MedTech Inc. Reports Fourth Quarter (Unaudited) and Full Year 2025 Financial Results; Reaffirmed Full Year 2026 Financial Guidance
FORT WORTH, TX, March 24, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commerciali...
Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds
Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX ® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the stand...
Sanara MedTech Transcript: TD Cowen 46th Annual Health Care Conference
The company has transitioned to a pure-play surgical wound care focus, achieving strong revenue growth and expanding its reach to over 4,000 facilities. With a robust product pipeline, stable high margins, and a hybrid sales model, it targets further growth through new product launches, expanded facility penetration, and selective M&A.
Sanara MedTech Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
FORT WORTH, TX, March 03, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commerciali...
Sanara MedTech Inc. to Participate in the TD Cowen 46th Annual Health Care Conference on March 3rd
FORT WORTH, TX, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializ...
Sanara MedTech Inc. Reports Unaudited Preliminary Financial Results for the Fourth Quarter and Full Year 2025; Introduces Full Year 2026 Financial Guidance
FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developin...
Sanara MedTech Inc. Receives Innovative Technology Contract from Vizient for BIASURGE® Advanced Surgical Solution
Contract awarded for products that bring improvement to the healthcare industry FORT WORTH, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” ...
Sanara MedTech Inc. and Biomimetic Innovations Provide Update on OsStic™
Poised for U.S. market launch in Q1 2027 following the achievement of recent milestones and OsStic's granted patent in 2025 FORT WORTH, TX, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sana...
Sanara MedTech to Participate in the Piper Sandler 37th Annual Healthcare Conference on December 3rd
FORT WORTH, TX, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializ...
Sanara MedTech Earnings Call Transcript: Q3 2025
Q3 2025 saw 22% revenue growth, margin expansion, and strong operating leverage, driven by core surgical products. THP operations were discontinued to focus on the surgical segment, with continued investment in product innovation and commercial expansion.
Sanara MedTech Inc. Reports Third Quarter 2025 Financial Results (Unaudited)
Net Revenue Increased 22% Year-Over-Year in Q3; Increased 25% Year-Over-Year in First Nine Months of 2025 FORT WORTH, TX, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,...
Sanara MedTech Inc. Announces Strategic Realignment to Focus on Surgical Business
Completes Evaluation of Strategic Alternatives for Tissue Health Plus Segment FORT WORTH, TX, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nas...
Sanara MedTech to Report Third Quarter 2025 Financial Results on November 12, 2025
FORT WORTH, TX, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformativ...
Sanara MedTech Transcript: Cantor Global Healthcare Conference 2025
Leadership transition and expanded management position the company for future growth. Strong Q2 results were driven by balanced performance in soft tissue and bone repair, with significant upside in contracted facilities and a robust product pipeline, including OsStic expected in 2027.
Sanara MedTech Inc. Announces Chief Executive Officer Transition
Seth Yon Appointed President, Chief Executive Officer and Director; Ron Nixon to Remain Executive Chairman FORT WORTH, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Compan...
Sanara MedTech Inc. to Present at the Cantor Global Healthcare Conference on September 3, 2025
FORT WORTH, TX, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializ...
Sanara MedTech Earnings Call Transcript: Q2 2025
Q2 2025 saw 28% revenue growth, improved profitability, and strong cash flow, led by the surgical segment. Strategic alternatives are being explored for THP, with reduced investment planned. The company remains focused on growth, innovation, and capital preservation.
Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)
Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiar...
Sanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025
FORT WORTH, TX, July 15, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformativ...
Sanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot Program
Pilot program designed to provide real-world evidence in the use of Tissue Health Plus' technology platform FORT WORTH, TX, July 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Compan...
Sanara MedTech Earnings Call Transcript: Q1 2025
Q1 2025 saw 26% revenue growth, strong gross margin, and expanded distribution, but net loss widened due to higher expenses and investments in new technology. Sanara Surgical drove growth, while Tissue Health Plus advanced its tech platform and pilot program.
Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)
Q1 Net Revenue Increased 26% Year-Over-Year FORT WORTH, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology com...